Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Preclinical to clinical utility of ROCK inhibitors in cancer
Jaume Barcelo, Rémi Samain, Victoria Sanz‐Moreno
Trends in cancer (2023) Vol. 9, Iss. 3, pp. 250-263
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Suman Mukhopadhyay, Hsin‐Yi Huang, Ziyan Lin, et al.
Cancer Research (2023) Vol. 83, Iss. 24, pp. 4095-4111
Open Access | Times Cited: 37
Shared signaling pathways and comprehensive therapeutic approaches among diabetes complications
Moein Ebrahimi, Hamid Ahmadieh, Mozhgan Rezaei Kanavi, et al.
Frontiers in Medicine (2025) Vol. 11
Open Access | Times Cited: 1
Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer Therapeutics
Manish Kumar
(2025)
Closed Access | Times Cited: 1
Spatially exploring RNA biology in archival formalin-fixed paraffin-embedded tissues
Zhiliang Bai, Dingyao Zhang, Yan Gao, et al.
Cell (2024) Vol. 187, Iss. 23, pp. 6760-6779.e24
Open Access | Times Cited: 8
Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer Therapeutic
Manish Kumar
Authorea (Authorea) (2025)
Open Access
Design, Synthesis, and Evaluation of Piperazine‐7‐Deazapurine Based Thiazolidone Derivatives as Novel ROCK Inhibitors
Sandeep Kumar Thoota, Suresh Maddila, Sai Kiran S. S. Pindiprolu, et al.
ChemistrySelect (2025) Vol. 10, Iss. 3
Closed Access
Pioneering first-in-class HDAC-ROCK inhibitors as potential multitarget anticancer agents
Milan Beljkaš, Dušan Ružić, Ana Djurić, et al.
Future Medicinal Chemistry (2025), pp. 1-15
Closed Access
CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells
Rémi Samain, Óscar Maiques, Joanne Monger, et al.
Science Advances (2023) Vol. 9, Iss. 42
Open Access | Times Cited: 10
Role of ROCK signaling in virus replication
Ram Kumar, Sanjay Barua, Bhupendra Nath Tripathi, et al.
Virus Research (2023) Vol. 329, pp. 199105-199105
Open Access | Times Cited: 8
Inhibitors of Rho/MRTF/SRF Transcription Pathway Regulate Mitochondrial Function
Pankaj Patyal, Xiaomin Zhang, Ambika Verma, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 392-392
Open Access | Times Cited: 2
Discovery of a novel ROCK2 ATP competitive inhibitor by DNA-encoded library selection
Chenhua Zhang, Yu‐Chih Liu, Depu Wang, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 699, pp. 149537-149537
Open Access | Times Cited: 1
The Precision Oncology Approach to Molecular Cancer Therapeutics Targeting Oncogenic Signaling Pathways is a Means to an End
Manish Kumar
(2024)
Open Access | Times Cited: 1
Role and targeting of the AGC kinase family in pulmonary fibrosis (Review)
Chao Mei, Tao Chen, Xiangfei Huang, et al.
Experimental and Therapeutic Medicine (2024) Vol. 27, Iss. 5
Open Access | Times Cited: 1
Plakophilin 4 controls the spatio-temporal activity of RhoA at adherens junctions to promote cortical actin ring formation and tissue tension
Lisa Müller, René Keil, Markus Glaß, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 1
G12/13 signaling in asthma
E McDuffie, Reynold A. Panettieri, Charles P. G. Scott
Respiratory Research (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics
Lawrence W. Wu, Sung Joo Jang, Cameron Shapiro, et al.
Targeted Oncology (2024)
Open Access | Times Cited: 1
The ROCK-1/2 inhibitor RKI-1447 blocks N-MYC, promotes cell death, and emerges as a synergistic partner for BET inhibitors in neuroblastoma.
Adena Pepich, Conny Tümmler, Sara Ajamieh, et al.
Cancer Letters (2024) Vol. 605, pp. 217261-217261
Open Access | Times Cited: 1
Modulation of the Cytoskeleton for Cancer Therapy
Alex Matov
(2024)
Closed Access | Times Cited: 1
The molecular basis of tumor metastasis and current approaches to decode targeted migration-promoting events in pediatric neuroblastoma
Diana Corallo, Marco Dalla Vecchia, Daria Lazic, et al.
Biochemical Pharmacology (2023) Vol. 215, pp. 115696-115696
Closed Access | Times Cited: 4
MRCK as a Potential Target for Claudin-Low Subtype of Breast Cancer
Hirohito Yamaguchi, Ling‐Chu Chang, Olin Shih-Shin Chang, et al.
International Journal of Biological Sciences (2023) Vol. 20, Iss. 1, pp. 1-14
Open Access | Times Cited: 3
Rho Kinase (ROCK) Inhibitors for the Treatment of Glaucoma
Junhui Wu, Jing Wei, Haoliang Chen, et al.
Current Drug Targets (2023) Vol. 25, Iss. 2, pp. 94-107
Open Access | Times Cited: 3
ROCK inhibition reduces the sensitivity of mutant p53 glioblastoma to genotoxic stress through a Rac1-driven ROS production
Yuli Thamires Magalhães, Fábio Luís Forti
The International Journal of Biochemistry & Cell Biology (2023) Vol. 164, pp. 106474-106474
Closed Access | Times Cited: 2
The Precision Oncology Approach to Molecular Cancer Therapeutics Targeting Oncogenic Signaling Pathways is a Means to an End
Manish Kumar
SSRN Electronic Journal (2024)
Open Access
The Precision Oncology Approach to Molecular Cancer Therapeutics Targeting Oncogenic Signaling Pathways is a Means to an End
Manish Kumar
(2024)
Open Access
LINC00645 inhibits renal cell carcinoma progression by interacting with HNRNPA2B1 to regulate the ROCK1 mRNA stability
Hao Li, Han Xu, Liang Song, et al.
Gene (2024) Vol. 905, pp. 148232-148232
Closed Access
Page 1 - Next Page

Scroll to top